NIAID Plans $20M for New Biodefense Countermeasures, Dx, Rx, Vaccines | GenomeWeb

NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Diseases plans to spend up to $20 million in fiscal year 2014 to fund efforts to develop lead candidates for diagnostics, therapeutics, and vaccines, that can be used as biodefense countermeasures against certain pathogens and toxins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.